مقالات پذیرفته شده در سومین کنگره بین المللی زیست پزشکی
Prognostic Value of Stanniocalcin 1 in solid tumors: A systematic review and meta-analysis
Prognostic Value of Stanniocalcin 1 in solid tumors: A systematic review and meta-analysis
Nikoo Saeidi,1Maryam Moradi Binabaj,2Amir Avan,3Majid Khazaei,4Seyed Mahdi Hassanian,5,*
1. Student Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran 2. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction: Stanniocalcin (STC) is a homo-dimeric glycoprotein hormone that is involved in calcium-phosphate homeostasis. Recent studies have revealed an association between STC1 expression with metastasis, invasion, and cancer progression.
Methods: A systematic search through different databases including PubMed, Embase, Web of Science, Scopus, Cochrane Library and Google Scholar limited to English language and human studies was performed. A total of 18 studies were included in this meta-analysis.
Results: In the pooled analysis the STC1 overexpression was significantly associated with tumor differentiation (OR=0.25, 95% CI=0.08-0.74), P=0.01), lymph invasion (OR=2.59, 95% CI=1.12-5.96, P=0.026), stage (OR=3.8 95% CI=2.01-7.16, P<0.001) and gender (OR=3.91, 95% CI= 2.16-7.06, P<0.001). In addition, results of pooled data analysis indicated that increased STC1 expression is associated with shorter PFS (HR=1.63, 95% CI=1.32-2.01; P=0.00) in all cancer patients. Moreover, overexpression of STC1 was significantly associated with worse OS with combined HR of 2.008 (95% CI=1.48-2.71, P<0.001). However, there was no significant relationship between GI cancers and OS (HR=1.457, 95% CI: 0.855-2.482, P=0.16).
Conclusion: In conclusion, the current meta-analysis demonstrated that STC1 expression level is significantly associated with poor OS and PFS in cancer patients. These results support the prognostic potential of STC1 as a novel biomarker in cancer patients.